The U.S. Food and Drug Administration (FDA) has granted Guerbet breakthrough device designation for Lipiojoint, a liquid embolic agent intended to alleviate pain and the burden of reduced mobility in patients with knee osteoarthritis.
Guerbet has developed Lipiojoint for genicular artery embolization, a minimally invasive procedure performed by interventional radiologists. The agent embolizes the knee synovial neovessels that appear in knee osteoarthritis, according to the firm.
